Rezolute, Inc.近日就其先天性高胰岛素血症候选药物Sunrize研究所取得的关键性III期临床数据，向外界通报了美国食品药品监督管理局（FDA）的最新审查动态。该公司在公告中详细说明了监管机构目前对该项研究结果进行评估的进展情况，但未透露具体的审批时间表或额外细节。
Rezolute, Inc.近日就其先天性高胰岛素血症候选药物Sunrize研究所取得的关键性III期临床数据，向外界通报了美国食品药品监督管理局（FDA）的最新审查动态。该公司在公告中详细说明了监管机构目前对该项研究结果进行评估的进展情况，但未透露具体的审批时间表或额外细节。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.